Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Pediatric Hematology/Oncology
What is the maximum number of metastatic sites you would treat with consolidative radiation for a patient with high-risk neuroblastoma?
Answer from: Radiation Oncologist at Community Practice
5 sites, per ANBL 1531
Comments
Radiation Oncologist at St Jude Children's Research Hospital
I would agree with @Joseph E. Panoff, and add that...
697
Sign In
or
Register
to read more
3695
Related Questions
In pediatric patients with Hodgkin lymphoma who have a partial response after chemotherapy and multiple disease sites above and below the diaphragm, how do you approach radiotherapy planning considering cumulative dose and toxicity?
How will you treat an uterine embryonal rhabdomyosarcoma with regional node involvement resected to involved parametrial margins?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
How would you advise a younger patient with residual/recurrent optic nerve meningioma, proceeding with radiotherapy, about the risks of malignant transformation or induction of other brain malignancies because of radiation?
What are the best radiation therapy options for a young adult with 3 brain metastases from myeloid sarcoma that hasn’t responded well to intrathecal therapy?
In pediatric Hodgkin lymphoma with symptomatic splenomegaly, what radiotherapy dose is recommended?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
How do you consider SBRT relative to other emerging therapies for pediatric sarcomas, such as proton therapy or immunotherapy, in terms of efficacy and safety?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?
I would agree with @Joseph E. Panoff, and add that...